|

Lupus Clinical Trials in Washington, DC

26 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersPhase 1/2<1 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Phase 2<1 mi
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions—<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPhase 3<1 mi
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusPhase 3<1 mi
Research Accelerated by You Lupus Registry—<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDPhase 26 mi
Study of Systemic Lupus Erythematosus—6 mi
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic DermatitisPhase 16 mi
Patient-Centered Assessment of Symptoms and Outcomes—6 mi
Deciphering the Genetic Architecture of Autoimmune Diseases—6 mi
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus ErythematosusPhase 1/26 mi
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires—6 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPhase 1/26 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants—14 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 314 mi
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisPhase 315 mi
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN—35 mi
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)—35 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Phase 135 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 235 mi
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Phase 335 mi
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusPhase 335 mi
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusPhase 335 mi
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)—35 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.